STAAR Surgical Management

Management criteria checks 1/4

STAAR Surgical's CEO is Tom Frinzi, appointed in Jan 2023, has a tenure of 1.92 years. total yearly compensation is $10.22M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.046% of the company’s shares, worth €558.09K. The average tenure of the management team and the board of directors is 1.9 years and 3.2 years respectively.

Key information

Tom Frinzi

Chief executive officer

US$10.2m

Total compensation

CEO salary percentage7.7%
CEO tenure1.9yrs
CEO ownership0.05%
Management average tenure1.9yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tom Frinzi's remuneration changed compared to STAAR Surgical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 27 2024n/an/a

US$22m

Jun 28 2024n/an/a

US$17m

Mar 29 2024n/an/a

US$15m

Dec 29 2023US$10mUS$788k

US$21m

Sep 29 2023n/an/a

US$20m

Jun 30 2023n/an/a

US$26m

Mar 31 2023n/an/a

US$33m

Dec 30 2022US$274kn/a

US$40m

Sep 30 2022n/an/a

US$38m

Jul 01 2022n/an/a

US$34m

Apr 01 2022n/an/a

US$29m

Dec 31 2021US$250kn/a

US$28m

Oct 01 2021n/an/a

US$23m

Jul 02 2021n/an/a

US$21m

Apr 02 2021n/an/a

US$11m

Jan 01 2021US$182kn/a

US$6m

Compensation vs Market: Tom's total compensation ($USD10.22M) is above average for companies of similar size in the German market ($USD1.65M).

Compensation vs Earnings: Tom's compensation has increased by more than 20% in the past year.


CEO

Tom Frinzi (68 yo)

1.9yrs

Tenure

US$10,220,581

Compensation

Mr. Thomas G. Frinzi, also known as Tom, serves as Executive Chairman of the Board at ViaLase, Inc. since November 2022 and joined the company in November 2022. He serves as Executive Chair at Aurion Biote...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Frinzi
President1.9yrsUS$10.22m0.046%
€ 558.1k
Patrick Williams
Chief Financial Officer4.4yrsUS$2.82m0.070%
€ 840.5k
Warren Foust
Chief Operating Officer1.7yrsUS$3.42m0.0089%
€ 106.9k
Keith Holliday
Chief Technology Officer7.8yrsUS$2.41m0.036%
€ 435.8k
Scott Barnes
Chief Medical Officer7.2yrsUS$2.48m0.064%
€ 768.5k
Brian Moore
Vice President of Investor Relations & Corporate Developmentno datano datano data
Nathaniel Sisitsky
General Counsel & Corporate Secretaryless than a yearno datano data
Nancy Sabin
Chief Marketing Officerless than a yearno datano data
James Francese
Senior Vice President of Commercial Operations - North America & APAC8.1yrsUS$2.54m0.060%
€ 727.2k
Magda Michna
Chief Clinical1.7yrsno data0.0061%
€ 73.8k
Robert Studholme
Senior Vice President of Operationsno datano data0.066%
€ 796.5k

1.9yrs

Average Tenure

60.5yo

Average Age

Experienced Management: SR3's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Thomas Frinzi
President4.5yrsUS$10.22m0.046%
€ 558.1k
Stephen Farrell
Lead Independent Director8.9yrsUS$294.87k0.031%
€ 371.7k
Aimee Weisner
Independent Director2.5yrsUS$259.96k0.031%
€ 376.5k
Lilian Zhou
Independent Directorless than a yearUS$99.69k0.0093%
€ 112.1k
Brian Williams
Member of Optometric Advisory Council16.1yrsno datano data
Arthur Crosswell Butcher
Independent Directorless than a yearno data0.0085%
€ 103.2k
Wei Jiang
Independent Directorless than a yearno data0.0072%
€ 86.9k
Elizabeth Yeu
Independent Director3.9yrsUS$249.99k0.010%
€ 125.0k

3.2yrs

Average Tenure

55yo

Average Age

Experienced Board: SR3's board of directors are considered experienced (3.2 years average tenure).